By abhat@reaganud… on
Phone
+41 91 697 6370
Email
qarziba@farmamondo.com
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/results?cond=&term=Eusa&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=c&recrs=d&recrs=f&recrs=k
EA Page
https://www.eusapharma.com/therapy-areas/managed-access-programme/
COVID-19 Information

Eusa Pharma and the Papa Giovanni XXIII Hospital, Bergamo, Italy announce initiation of an observational case-control study of Siltuximab in patients with COVID-19 who have developed serious respiratory complications.

For more information: https://www.eusapharma.com/news/eusa-pharma-and-the-papa-giovanni-xxiii-hospital/

Stage
Phase 2
Company Type
Late Onset Intervention